Frank Diamond

Intermountain Healthcare’s checklist for providers cut mortality rates for this fast-moving, and sometimes lethal, condition

In November 2001, when the New England Journal of Medicine published a study about how to better treat severe sepsis, clinician executives at Intermountain Healthcare took note. Intermountain, an integrated system that owns its hospitals, operates 22 emergency departments that evaluate about 450,000 patients a year. In 2009 and 2010, about 2,000 patients with sepsis were treated.

“It doesn’t happen with alarming regularity, but when it does, the consequences can be dire,” says Todd L. Allen, MD, assistant quality officer at the Institute for Healthcare Delivery and Research at Intermountain.

Sepsis protocol

In 2004, the health system got to work, conducting a systemwide survey, planning a course of action. Intensive deployment of the program started in 2008. The effort revolves around a sepsis protocol that cut the mortality rate from 25 percent to around 9 percent in 2011.

The Intermountain process required 11 clinical elements during the first 24 hours of treatment. “We call it a sepsis bundle,” Allen says, “a bundle being a collection of a number of important care elements within a clinical process.”

Some were diagnostic goals such as laboratory testing and collecting blood cultures. Some were therapeutic goals like early administration of antibiotics that support fluid resuscitation. “If you missed just one element by even a minute, the bundle was considered a fail,” he says.

Allen credits Intermountain’s decades-long effort to provide doctors with up-to-date data as one reason for the success. Also, he cites a delivery mechanism that he calls clinical programs, which function like specialty departments, except that Intermountain does not organize by specialty but rather around clinical work processes.

The treatment bundle is overseen by Intermountain’s intensive medicine clinical program. “It’s made up of emergency medicine physicians, hospitalists, critical care physicians, transport specialists, respiratory therapists, radiologists, laboratory technicians, and other providers.”

The program runs in all 22 hospitals that Intermountain owns. “While most of the bundle is standardized, we tried to leave a lot of room for adaptation to the individual hospital. If the hospital wanted to identify the patient with sepsis and almost immediately tried to transfer him to the ICU and some of the early bundled elements occurred in the ICU, as long as they were done successfully in the first six hours, that was considered OK.”

Transferable

He considers the sepsis program “absolutely transferable” to nonintegrated health plans if they provide instant clinical feedback so providers can clearly see what they’re doing and how they’re doing it. “Anybody could do similar work,” says Allen.

“Much of what we do in health care can technically be considered quality waste. Projects like sepsis are really designed for eliminating waste.”

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.